-
Notice on the postponement of the 88th API China and the 26th CHINA-PHARM to December 6
Time of Update: 2022-11-05
Dear exhibitors, visitors and friends from the industry, In view of the recent epidemic situation in many places in China and the sporadic cases in Qingdao, according to the needs of epidemic preventi
-
The sales of quick-acting heart-saving pills exceeded 1 billion, and Darentang's performance was promising!
Time of Update: 2022-11-04
pharmacy In this issue, the big data platform of TCM industry of Tiandi Yuntu makes a brief analysis of the cost pressure of traditional Chinese medicine raw materials of enterprises from the perspective of raw materials involved in quick-acting heart-saving pills.
-
Behind the rising market of Angelica, opportunities and risks coexist!
Time of Update: 2022-11-04
has Figure 1: Resource distribution in the main producing areas of angelica Second, production changes: In the second quarter, the rate of dead seedlings of angelica increased due to high temperature and drought Figure 2: Temperature and rainfall in Gansu, Qinghai and Yunnan provinces from January to August 2022 From the perspective of temperature changes: the temperature in the first quarter of 2022 was low, and the high temperature in the second quarter was prominent.
-
The State Food and Drug Administration issues enterprise-related licenses at this level and comprehensively issues electronic licenses
Time of Update: 2022-11-04
(End) According to the China National Medical Products Administration: From November 1, 2022, the enterprise-related licenses issued by the State Food and Drug Administration at this level will be fully issued with electronic licenses.
-
New drug for atopic dermatitis (AD)! IL-13 inhibitor lebrikizumab enters review in the EU: long-lasting removal of skin lesions, relieves itching!
Time of Update: 2022-11-04
Results showed that patients who received lebrikizumab (every 2 weeks) during the 16-week induction phase of two monotherapy trials (ADvocate 1 and 2) and achieved a clinical response at week 16 continued to receive lebrikizumab during the maintenance phase for up to one year, achieving durable lesion clearance and itching relief.
-
Approaching the end of the year, the pharmaceutical industry has reappeared in a wave of layoffs!
Time of Update: 2022-11-04
At the end of October, Dutch medical device manufacturer Philips announced urgent actions to improve performance, including an immediate layoff of around 4,000 employees worldwide and an expected charge of about 300 million euros in the coming quarters.
-
Public hospital market, these pharmaceutical companies have the largest sales (with list)
Time of Update: 2022-11-04
4% The growth rate of proprietary Chinese medicine surpassed that of chemical drugs for the first time in ten years From the perspective of the distribution of drugs, in the first half of 2022, chemical drugs accounted for the largest proportion in public medical institutions, exceeding 66%, but their market position continued to decline, and sales decreased by 0.
-
Domestic vascular interventional surgical robot track ushered in "golden time"
Time of Update: 2022-11-04
A number of technical barriers need to be broken through Based on significant clinical advantages, vascular interventional surgical robots have gradually become a hot track, and their development direction is diversified.
-
Under the trend of innovation, the upstream and downstream of the pharmaceutical industry chain are increasing investment in research and development
Time of Update: 2022-11-04
com) Pharmaceutical companies are investing in R&D increasing Taking Warner Pharma as an example, on October 31, Warner Pharma disclosed its third quarter report for 2022.
com) Pharmaceutical companies are investing in R&D increasing Taking Warner Pharma as an example, on October 31, Warner Pharma disclosed its third quarter report for 2022.
-
More than 460 pharmaceutical companies disclosed the third quarterly report, and the net profit of this high-gloss enterprise exceeded 10 billion!
Time of Update: 2022-11-04
Among the 23 listed companies with net profit exceeding 2 billion yuan, 17 achieved year-on-year growth, including WuXi AppTec, Wantai Biologics, Mentor Biologics, Anxu Biologics, Kelleying, Renfu Pharmaceutical, BGI, etc.
-
Directly hit the Shanghai inhalation recombinant new coronavirus vaccination site
Time of Update: 2022-11-04
Shanghai launched the appointment registration for booster immunization of the inhaled recombinant new coronavirus vaccine (adenovirus vector type 5), and the reporter recently visited the Zhongshan Street Community Health Service Center in Songjiang District, Shanghai.
-
Centralized procurement accelerates and expands the scope The marketing transformation of pharmaceutical companies is imperative
Time of Update: 2022-11-04
So far, the state has organized 7 batches of centralized drug procurement, and the cumulative number of successful procurement of drugs has reached 294, with an average price reduction of more than 4
-
Deputy general managers of pharmaceutical companies set off a "wave of departures", and more than 7 "left" in October
Time of Update: 2022-11-04
Dafo Pharmaceutical issued an announcement that the company's board of directors received a resignation report submitted by Liu Zhanfeng, deputy general manager in charge of (production) on October 31, 2022, and Liu Zhanfeng resigned from the position of deputy general manager due to personal reasons, effective from October 31, 2022.
-
The head enterprises of domestic pharmaceutical machines have accelerated their overseas expansion and obtained the stepping stone of the high-end biopharmaceutical supply chain
Time of Update: 2022-11-04
With the aging of the population, the increase of people's awareness of health care, and the continuous improvement of the medical security system of various countries, the global biological drugs re
-
Random inspections of drugs in various places are frequent, and Chinese medicine pieces of substandard products still account for the majority
Time of Update: 2022-11-04
js?cdnversion='+~(-new Date()/36e5)];In order to ensure the quality and safety of drugs, relevant departments have frequently issued policies and strict supervision in recent years to promote the development of the pharmaceutical industry in a standardized direction.
-
In order to improve R&D and production efficiency, the pharmaceutical industry has become a trend with the help of intelligence
Time of Update: 2022-11-04
In order to improve R&D efficiency and reduce R&D investment, with the continuous development of science and technology in recent years, more and more enterprises and researchers have begun to apply artificial intelligence, big data, AI and other digital technologies to pharmaceutical R&D and production, trying to further improve the success rate of new drug research and development through artificial intelligence technology and AI algorithms, reduce R&D time and reduce manufacturing costs.
-
The National Medical Insurance Administration announced that the two pharmaceutical companies were assessed as "serious" untrustworthy
Time of Update: 2022-11-04
, Ltd. gave kickbacks or improper benefits to relevant personnel of a number of medical institutions in order to obtain additional trading opportunities, competitive advantages and sales quantities for the traditional Chinese medicine pieces it operated, equivalent to a total of more than 1.
-
Hengqin has issued special policies to support the development of the biomedical health industry
Time of Update: 2022-11-04
In addition, to promote the internationalization of "Macao Registration + Hengqin Production", while encouraging international registration, we will simultaneously support and encourage the introduction of imported new drugs, strengthen quality standardization management, and further enhance the internationalization level of the biomedical and health industry in the Cooperation Zone, with a cumulative total of up to 36 million yuan.
-
The first symptomatic treatment drug for schizophrenia! Roluperidone suffered a regulatory setback: rejected by the US FDA!
Time of Update: 2022-11-04
In August 2022, Minerva submitted a New Drug Application (NDA) to the FDA for roluperidone (dose 64mg): an oral small molecule compound that is an antagonist of serotonin 2A (5-HT2A) receptors, σ2 (sigma-2) receptors, α1A (alpha-1A) adrenergic receptors for the treatment of negative symptoms in patients with schizophrenia.
-
The innovation of traditional Chinese medicine has accelerated, and many pharmaceutical companies have achieved significant growth in performance in the third quarter
Time of Update: 2022-11-04
In addition, Wellcome Pharmaceutical also said that it attaches great importance to the research and development and innovation of traditional Chinese medicine, and achieved operating income of 474 million yuan and net profit attributable to the parent of 94 million yuan in the first three quarters of this year, a year-on-year increase of 1.
